Kinetics and seroprevalence of SARS-CoV-2 antibodies: a comparison of 3 different assays

Comparing seroprevalence and antibody kinetics in three different commercially available assays for SARS-CoV-2. Serostatus of COVID-19 patients was analyzed 5 months and 10 months after their infection, using three different assays: Diasorin LIAISON, Euroimmun, Abbott Diagnostics ARCHITECT. Seroposi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kahre, Elisabeth, Galow, Lukas, Unrath, Manja, Haag, Luise, Blankenburg, Judith, Dalpke, Alexander H., Lück, Christian, Berner, Reinhard, Armann, Jakob P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295301/
https://www.ncbi.nlm.nih.gov/pubmed/34290329
http://dx.doi.org/10.1038/s41598-021-94453-5
Descripción
Sumario:Comparing seroprevalence and antibody kinetics in three different commercially available assays for SARS-CoV-2. Serostatus of COVID-19 patients was analyzed 5 months and 10 months after their infection, using three different assays: Diasorin LIAISON, Euroimmun, Abbott Diagnostics ARCHITECT. Seropositivity at baseline differed significantly depending on the assay (Diasorin 81%, Euroimmun 83%, Abbott 59%). At follow-up antibody levels detected in the Diasorin assay were stable, while there was a significant loss in seropositivity in the Euroimmun and Abbott assays. There are significant differences in SARS-CoV-2 antibody kinetics based on the specific assay used.

Ejemplares similares